(Q44059662)

English

Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

0 references

2

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

3

object named as

Markus Letsch

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Artur Plonowski

1

object named as

Artur Plonowski

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

author name string

Magdalena Krupa

4

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Francine Hebert

5

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Rebeca Busto

6

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Kate Groot

7

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Jozsef L Varga

8

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

publication date

1 August 2002

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

52

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

173-182

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10105

21 January 2018

Peptide growth factors and prostate cancer: new models, new opportunities

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10105

21 January 2018

Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10105

21 January 2018

Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10105

21 January 2018

Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10105

21 January 2018

Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10105

21 January 2018

Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10105

21 January 2018

Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10105

21 January 2018

Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10105

21 January 2018

Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10105

21 January 2018

Mechanisms of Antineoplastic Action of Somatostatin Analogs

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10105

21 January 2018

Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10105

21 January 2018

Synthesis and biological activity of highly potent octapeptide analogs of somatostatin

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10105

21 January 2018

Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10105

21 January 2018

Mechanistic concepts in androgen-dependence of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10105

21 January 2018

Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10105

21 January 2018

Peptide analogs in the therapy of prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10105

21 January 2018

Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10105

21 January 2018

Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10105

21 January 2018

Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3).

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10105

21 January 2018

Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10105

21 January 2018

Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10105

21 January 2018

Inhibition of Angiogenesis by Somatostatin and Somatostatin-like Compounds Is Structurally Dependent

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10105

Suppression of tumor growth by growth hormone-releasing hormone antagonist JV-1-36 does not involve the inhibition of autocrine production of insulin-like growth factor II in H-69 small cell lung carcinoma

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10105

Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: evidence for an IGF-II autocrine growth loop

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10105

Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10105

Antagonistic Analogs of Growth Hormone-releasing Hormone: New Potential Antitumor Agents

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10105

Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10105

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.10105

Identifiers

10.1002/PROS.10105

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44059662&oldid=2119259574"